查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1735680

全球 BCG 结核病疫苗市场规模（按类型、应用、最终用户、区域范围）预测（至 2025 年）

Global BCG Tuberculosis (TB) Vaccine Market Size By Type (Immune, Therapy), By Application (Pediatrics, Adults), By End-User (Hospitals, Clinics) By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

BCG结核病疫苗市场规模及预测

预计 BCG 结核病 (TB) 疫苗市场规模将在 2024 年达到 5,349 万美元，到 2032 年将达到 7,264 万美元，在 2026-2032 年预测期内的复合年增长率为 3.90%。

  • BCG（卡介苗）疫苗主要用于治疗结核病。它是牛分枝桿菌的弱毒株，牛分枝桿菌与导致结核病的结核菌类似。
  • 这种疫苗在出生后不久就接种，适用于结核病风险较高的婴儿。卡介苗能够刺激免疫反应，保护婴儿免受致命结核病的侵害。它也用于治疗膀胱癌。

全球卡介苗结核病疫苗市场动态

影响 BCG 结核病疫苗市场的关键市场动态是：

关键市场驱动因素

  • 全球结核病发生率高企：全球结核病发生率持续居高不下是卡介苗疫苗业务的主要驱动力。根据世界卫生组织（WHO）《2023年全球结核病报告》，预计2022年将有1,060万人感染结核病，其中130万人为儿童。分析显示，结核病仍是世界上最致命的感染疾病之一，2022年造成130万人死亡。如此巨大的疾病负担凸显了有效结核病预防活动，尤其是卡介苗疫苗接种的持续必要性。
  • 政府投入和资金不断增加：政府对结核病控制的支持和资金筹措不断增加，正在推动卡介苗市场的发展。据遏制结核病伙伴关係组织 (Stop TB Partnership) 称，2022 年全球结核病资金筹措将达到 58 亿美元，创历史新高。然而，这仍低于《2018-2022 年全球终止结核病计画》中提出的 2022 年每年 130 亿美元的目标。对消除结核病工作的日益重视预计将增加疫苗接种支出。
  • 新兴国家意识的提升和疫苗接种计画的扩大：疫苗接种计画的扩大，尤其是在结核病高发的新兴国家，正在推动对卡介苗的需求。根据联合国儿童基金会的数据，全球卡介苗接种覆盖率已从2000年的85%上升至2019年的88%。在结核病流行的东南亚，2019年卡介苗接种覆盖率达到了95%。预计此类高负担地区覆盖率的提升趋势将持续下去，从而推动市场成长。

主要挑战

  • 卡介苗使用相关的副作用：卡介苗的副作用包括淋巴结肿大、高烧和注射部位皮肤感染。虽然这些副作用罕见，但却阻碍了疫苗的普及和市场的成长。因此，密切监测和控制副作用至关重要。
  • 对卡介苗有效性的担忧：人们对卡介苗预防新出现的结核病菌株的有效性有疑虑。如果疫苗对这些新出现的结核病菌株无效，将会减少需求并减缓市场成长。需要持续研究和改进，以保持卡介苗的有效性。
  • 供不应求：卡介苗短缺限制了市场扩张。供应链问题、生产挑战或产量短缺导致供不应求，限制了疫苗的供应，尤其是在结核病高负担国家。需要充足且稳定的供应来满足全球需求并减少结核病的发生率。

主要趋势：

  • 高结核病发病率推动全球需求：结核病的全球蔓延仍然是一个重大的公共卫生问题，尤其是在低度开发国家。世界卫生组织 (WHO) 预测，每年将出现数百万例结核病新病例，这将刺激对卡介苗的需求。世界各国政府认识到结核病控制的重要性，正在进行疫苗宣传活动，并投资建设医疗机构。
  • 关注儿童疫苗接种计画：儿童疫苗接种计画正变得越来越重要，尤其是在结核病高发生率地区。各国政府和卫生组织正优先为新生儿接种疫苗，以预防结核性脑膜炎等严重结核病。国际上进行的旨在意识提升的计画和宣传活动进一步强化了这一趋势，从而增加了对卡介苗的需求。
  • 新型候选疫苗的出现：新型及改良型结核病疫苗（包括重组卡介苗和次单位疫苗）目前正在研发中。这些候选疫苗旨在克服现有卡介苗的局限性，并提高其对各种结核病菌株的疗效。这些新型疫苗的上市预计将颠覆市场格局，并随着其临床试验和监管核准的推进推动未来成长。

目录

第一章 BCG结核病（TB）疫苗全球市场介绍

  • 市场介绍
  • 研究范围
  • 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

第四章 BCG结核病疫苗全球市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

5. 全球 BCG 结核病疫苗市场（按类型）

  • 概述
  • 免疫卡介苗
  • 治疗 BCG

6. 全球 BCG 结核病疫苗市场（依应用）

  • 概述
  • 孩子们
  • 成人

7. 全球 BCG 结核病疫苗市场（依最终用户）

  • 概述
  • 医院
  • 诊所

8. 全球 BCG 结核病疫苗市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 世界其他地区
    • 拉丁美洲
    • 中东

9. 全球结核病疫苗市场竞争格局

  • 概述
  • 各公司市场排名
  • 主要发展策略

第十章 公司简介

  • Merck
  • Sanofi Pasteur
  • Japan BCG Lab
  • China National Biotec
  • Serum Institute of India
  • Intervax
  • GSBPL

第十一章 附录

  • 相关调查
简介目录
Product Code: 35652

BCG Tuberculosis (TB) Vaccine Market Size and Forecast

BCG Tuberculosis (TB) Vaccine Market size was valued at USD 53.49 Million in 2024 and is projected to reach USD 72.64 Million by 2032, growing at a CAGR of 3.90% from 2026-2032.

  • The BCG (Bacillus Calmette-Guerin) vaccine is primarily used to treat tuberculosis. It is a weakened strain of Mycobacterium bovis, a microbe similar to M. tuberculosis that causes tuberculosis.
  • The vaccine is provided shortly after delivery, particularly to infants at high risk of tuberculosis. The BCG vaccine stimulates an immunological response, protecting babies and young children from deadly types of tuberculosis. It is also used to treat bladder cancer.

Global BCG Tuberculosis (TB) Vaccine Market Dynamics

The key market dynamics that are shaping the BCG Tuberculosis (TB) vaccine market include:

Key Market Drivers

  • High Global Tuberculosis Burden: The persistently high worldwide tuberculosis load is a major driver of the BCG vaccination business. According to the World Health Organization's Global Tuberculosis Report 2023, an estimated 10.6 million individuals became ill with tuberculosis in 2022, including 1.3 million children. According to the analysis, tuberculosis remains one of the world's worst infectious diseases, accounting for 1.3 million fatalities in 2022. This significant disease burden highlights the ongoing need for effective tuberculosis prevention efforts, particularly BCG vaccination.
  • Increasing Government Initiatives and Funding: Growing government support and financing for tuberculosis control initiatives is propelling the BCG vaccine market. According to the Stop TB Partnership, global TB financing reached $5.8 billion in 2022, the highest level reported to date. However, this falls short of the $13 billion yearly expenditure required by 2022, as indicated by the Global Plan to End Tuberculosis 2018-2022. The increased emphasis on tuberculosis elimination is anticipated to enhance expenditure on vaccination efforts.
  • Rising Awareness and Expanding Immunization Programs in Developing Countries: Expanding immunization programs, particularly in developing countries with high tuberculosis burdens, are driving up demand for BCG vaccines. According to UNICEF, global BCG vaccine coverage has increased from 85% in 2000 to 88% in 2019. In South-East Asia, where tuberculosis is endemic, BCG coverage reached 95% in 2019. This trend of expanding coverage in high-burden areas is projected to continue, resulting in market growth.

Key Challenges:

  • Side Effects Associated with the Use of BCG Vaccine: The BCG vaccine has side effects such as swollen lymph nodes, high fever, and skin infections at the injection site. Despite their rarity, these side effects hinder vaccination acceptance and market growth. Careful monitoring and control of any adverse effects is essential.
  • Concerns Regarding the Efficacy of BCG Vaccines: There are questions regarding the BCG vaccine's effectiveness to protect against new tuberculosis strains that have appeared. If the vaccination is ineffective against these new strains, it diminishes demand and slows market growth. Ongoing research and improvement are required to ensure that the BCG vaccine stays effective.
  • Shortage of Supply: A lack of BCG vaccines limits market expansion. Supply chain problems, manufacturing challenges, or underproduction cause shortages and restrict the availability of the vaccine, particularly in high-burden nations. Meeting global demand and reducing tuberculosis require an adequate and stable supply.

Key Trends:

  • Increasing Global Demand Due to High TB Prevalence: The global prevalence of tuberculosis remains a major public health concern, particularly in underdeveloped nations. The World Health Organization (WHO) predicts millions of new tuberculosis infections each year, fueling demand for the BCG vaccine. As governments acknowledge the importance of combating tuberculosis, they are launching vaccination campaigns and investing in healthcare facilities, which are projected to considerably enhance market growth in the future years.
  • Focus on Childhood Immunization Programs: Childhood immunization programs are becoming increasingly important, particularly in areas with high tuberculosis prevalence. Governments and health organizations are prioritizing neonatal vaccination to prevent serious types of tuberculosis, such as TB meningitis. This focus is reinforced by international programs and campaigns focused on raising awareness about tuberculosis prevention, which drives higher demand for the BCG vaccine.
  • Emergence of Novel Vaccine Candidates: New and improved tuberculosis vaccines, such as recombinant BCG vaccines and subunit vaccinations, are now under development. These candidates seek to overcome the limitations of the current BCG vaccine and improve its efficacy against various tuberculosis strains. The prospective launch of these novel vaccines is projected to disrupt the market environment and drive future growth as they go through clinical trials and regulatory approval.

Global BCG Tuberculosis (TB) Vaccine Market Regional Analysis

Here is a more detailed regional analysis of the BCG Tuberculosis (TB) vaccine market:

Asia Pacific:

  • According to Verified Market Research, the Asia Pacific region is estimated to dominate over the forecast period. The Asia Pacific area has a disproportionately high tuberculosis load, fueling up demand for BCG vaccines. According to the World Health Organization's Global Tuberculosis Report 2023, six of the eight countries responsible for two-thirds of global tuberculosis cases in 2022 were in Asia Pacific: India (27%), Indonesia (9.2%), China (7.4%), the Philippines (7%), Pakistan (5.7%), and Bangladesh (3.6%). This high disease load demands ongoing and extended immunization efforts in the region.
  • BCG immunization is primarily targeted at the Asia Pacific region's huge and rising pediatric population. According to the United Nations Population Division, Asia is home to about half of the world's children, with a projected 1.2 billion under the age of 18 in 2020. According to UNICEF, India, which has the region's highest pediatric population, there were roughly 27 million births in 2022. The region's BCG vaccine demand is driven by its large and expanding pediatric population.
  • Furthermore, many Asia Pacific countries are currently working to improve their healthcare infrastructure and increase immunization coverage. For example, according to WHO and UNICEF estimates of national vaccination coverage, BCG vaccine coverage in Southeast Asia increased from 87% in 2000 to 95% by 2022. Since 2000, BCG coverage in the Western Pacific region, which includes China and other East Asian countries, has generally been higher than 95%. This trend of upgrading healthcare systems and extending vaccination programs is a major driver of the BCG vaccine market in the region.

North America:

  • North America is estimated to exhibit significant growth during the forecast period. North America, particularly the United States, sees a lot of immigration from countries with high tuberculosis rates, which drives up the demand for BCG immunization. According to the Centers for Disease Control and Prevention (CDC), 8,300 tuberculosis (TB) infections were reported in the United States in 2022. The CDC also states that foreign-born individuals account for the bulk of tuberculosis cases in the United States, with an incidence rate 14 times higher than that of U.S.-born people in 2022. This demographic pattern highlights the importance of BCG immunization in the region.
  • Furthermore, the BCG vaccine is being utilized as an immunotherapy for bladder cancer, which is generating demand in North America. According to the American Cancer Society, approximately 82,290 new cases of bladder cancer (62,460 in men and 19,830 in women) are expected to be detected in the United States by 2023. The association also believes that bladder cancer is the fourth most frequent malignancy in men. The increasing prevalence of bladder cancer in North America has increased the need for the BCG vaccine as a therapy option.

Europe:

  • Europe region is estimated to exhibit substantial growth during the forecast period. Europe has seen a considerable influx of immigrants from countries with high tuberculosis prevalence, pushing up demand for BCG vaccine. According to the European Centre for Disease Prevention and Control (ECDC), foreign-born people accounted for 29.4% of TB infections in the EU/EEA in 2019. Foreign-born cases ranged from 0% to 95.7% in reporting nations. This demographic transition has led to a greater emphasis on tuberculosis prevention techniques, such as BCG vaccination for high-risk groups.
  • Furthermore, TB vaccine research and development in Europe is on the rise, with enhanced BCG formulations among the highlights. Between 2003 and 2020, the European & Developing Countries Clinical Trials Partnership (EDCTP) contributed more than €157 million in 52 grants for clinical research on tuberculosis vaccines. This investment comprises around 15% of EDCTP's total portfolio. The increased R&D focus is likely to stimulate innovation in the BCG vaccine industry and potentially broaden its applications.

BCG Tuberculosis (TB) Vaccine Market: Segmentation Analysis

The BCG Tuberculosis (TB) Vaccine Market is segmented based on Type, Application, End-User, and Geography.

BCG Tuberculosis (TB) Vaccine Market, By Type

  • Immune BCG
  • Therapy BCG

Based on Type, the market is segmented into Immune BCG and Therapy BCG. The immune BCG segment is estimated to dominate the BCG Tuberculosis (TB) vaccine market due to immune BCG's success in preventing tuberculosis, which has led to widespread acceptance and incorporation into national immunization programs around the world. The lack of alternative vaccinations for immune BCG has further strengthened its standing, as healthcare providers continue to rely on it for tuberculosis prevention.

BCG Tuberculosis (TB) Vaccine Market, By Application

  • Pediatrics
  • Adults

Based on Application, the market is segmented into Pediatrics and Adults. The pediatrics segment is estimated to dominate the BCG Tuberculosis (TB) vaccine market. BCG vaccination is primarily administered to infants and young children because it gives up to 80% protection against severe types of pediatric tuberculosis, such as TB meningitis. Children have a higher risk of contracting tuberculosis than adults. Continuous government measures for tuberculosis immunization in children are helping to drive the segment's growth.

BCG Tuberculosis (TB) Vaccine Market, By End-User

  • Hospitals
  • Clinics

Based on End-User, the BCG Tuberculosis (TB) vaccine market is divided into Hospitals and Clinics. According to VMR analyst, the hospital segment is estimated to dominate the market over the forecast period due to hospitals' extensive healthcare services, which include immunization programs for babies and at-risk groups. Hospitals are frequently equipped with the required infrastructure and skilled personnel to properly deliver the BCG vaccine, making them an ideal location for TB preventive initiatives. Furthermore, hospitals play an important role in handling tuberculosis patients, which helps to secure their market position.

BCG Tuberculosis (TB) Vaccine Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Based on Geography, the BCG Tuberculosis (TB) vaccine market is classified into North America, Europe, Asia Pacific, and the Rest of the World. The Asia Pacific region is expected to dominate the market during the forecasted period. This domination is mostly due to the high incidence of tuberculosis in countries such as India and China, which account for a sizable proportion of worldwide TB cases. Government attempts to increase vaccine coverage, as well as raising knowledge about tuberculosis prevention, contribute to the region's strong market position. As a result, Asia Pacific is projected to continue to drive the BCG vaccination market.

Key Players

  • The "BCG Tuberculosis (TB) Vaccine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Merck, Sanofi Pasteur, Japan BCG Lab, China National Biotec, Serum Institute of India, Intervax, and GSBPL.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

  • BCG Tuberculosis (TB) Vaccine Market Recent Developments
  • In July 2021, The New Jersey-based Hackensack Meridian Center for Discovery and Innovation (CDI) announced that it had received USD 6.4 million in funding from the National Institutes of Health to investigate a novel idea for a tuberculosis vaccine. The CDI team has suggested that BCG would be enhanced by designing it to promote B-cell proliferation and survival.
  • In March 2022, The Serum Institute of India Pvt. Ltd. requested the Drugs Controller General of India, seeking the emergency usage of authorization for its recombinant BCG vaccination to combat tuberculosis. Throughout the projected period, the BCG vaccine market will benefit from the approval of this vaccine.
  • In January 2023, The WHO intended to establish a new "TB Vaccine Accelerator Council". The committee will speed up the formation of a high-level coalition comprising international organizations, donors, end users, and governments to identify and address obstacles to the development of tuberculosis vaccines like BCG. It will also help authorize and implement innovative TB vaccines

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL BCG TUBERCULOSIS (TB) VACCINE MARKET

  • 1.1 Introduction of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL BCG TUBERCULOSIS (TB) VACCINE MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL BCG TUBERCULOSIS (TB) VACCINE MARKET, BY TYPE

  • 5.1 Overview
  • 5.2 Immune BCG
  • 5.3 Therapy BCG

6 GLOBAL BCG TUBERCULOSIS (TB) VACCINE MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Pediatrics
  • 6.3 Adults

7 GLOBAL BCG TUBERCULOSIS (TB) VACCINE MARKET, BY END-USER

  • 7.1 Overview
  • 7.2 Hospitals
  • 7.3 Clinics

8 GLOBAL BCG TUBERCULOSIS (TB) VACCINE MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East

9 GLOBAL BCG TUBERCULOSIS (TB) VACCINE MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Merck
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Sanofi Pasteur
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Japan BCG Lab
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 China National Biotec
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 Serum Institute of India
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Intervax
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 GSBPL
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments

11 Appendix

  • 11.1 Related Research